Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate.

Abstract

Perhexiline maleate, originally classified as a calcium antagonist, is in use as an antianginal agent. The mechanism of its protective effect is unknown, but there is speculation that it involves a modification of myocardial substrate utilization, in which glycolytic sources are used rather than fatty acids. This hypothesis was tested by employing [13C]NMR… (More)

Topics

Cite this paper

@article{Jeffrey1995DirectET, title={Direct evidence that perhexiline modifies myocardial substrate utilization from fatty acids to lactate.}, author={F. Mark H. Jeffrey and L. F. Alvarez and V. Diczku and Alissa Sherry and Craig Malloy}, journal={Journal of cardiovascular pharmacology}, year={1995}, volume={25 3}, pages={469-72} }